Raloxifene decreases cell viability and migratory potential in prostate cancer cells (LNCaP) with GPR30/GPER1 involvement
| Autor: | André Teves A.G. de Freitas, Cristiane Figueiredo Pinho, Wellerson Rodrigo Scarano, Leonardo O. Mendes, Flávia Karina Delella, Giovanna Cassone Salata, Ariana Musa de Aquino, Bianca F. Gonçalves, Luis A. Justulin |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Cell Survival MAP Kinase Signaling System Pharmaceutical Science Receptors G-Protein-Coupled 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Cell Movement Cell Line Tumor LNCaP medicine Humans Raloxifene Viability assay DAPI Receptor Protein kinase B 030304 developmental biology Pharmacology 0303 health sciences Migration Assay Chemistry Prostate Prostatic Neoplasms Middle Aged Molecular biology Receptors Estrogen Apoptosis Raloxifene Hydrochloride 030220 oncology & carcinogenesis Proto-Oncogene Proteins c-akt Signal Transduction medicine.drug |
| Zdroj: | Journal of Pharmacy and Pharmacology. 71:1065-1071 |
| ISSN: | 2042-7158 0022-3573 |
| Popis: | Objectives This study evaluated raloxifene (ral) effects on LNCaP prostate tumour cells modulating the activity of GPER1/GPR30 receptors. Methods LNCaP cells were submitted for 40/120 min and 12 h to the following treatments: C: RPMI + DMSO; R: RPMI + Ral; G: RPMI + Ral + G15 (GPER1 antagonist). Trypan blue staining measured cell viability. Migratory potential (12 h) was measured by transwell migration test in translucent inserts, which were then stained with DAPI and analysed under a fluorescence microscope for quantification. Cells from 40- and 120-min treatments were subjected to protein extraction to the study of AKT, pAKT, ERK, pERK, ERβ and SIRT1. Key findings There is a reduction in cellular viability in R compared to C at all evaluated times, and an increased cell viability in G when compared to R; cell viability was similar in C and G in all times studied. The migration assay demonstrated a significant decrease in migration potential of tumour cells in R compared to C and G. Ral treatment reduced pERK expression and increased pAKT in the treated groups after 40 min, pointing out to an antiproliferative and apoptotic effect in the GPER1-controlled rapid-effect pathways. Conclusions Raloxifene was able to modulate GPER1 in LNCaP prostate tumour cells, decreasing cell viability and their migratory potential. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text